PriceTargets.com logo

AIM ImmunoTech - AIM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.75
  • Forecasted Upside: 1,206.41%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.21 As of 12/17/2024 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for AIM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AIM ImmunoTech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AIM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AIM

Analyst Price Target is $2.75
▲ +1,206.41% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for AIM ImmunoTech in the last 3 months. The average price target is $2.75, with a high forecast of $4.50 and a low forecast of $1.00. The average price target represents a 1,206.41% upside from the last price of $0.21.

This chart shows the closing price for AIM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in AIM ImmunoTech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/10/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$5.00 ➝ $4.50
10/22/2024Maxim GroupLower TargetBuy ➝ Buy$2.00 ➝ $1.00
9/3/2024Ascendiant Capital MarketsLower TargetBuy ➝ Buy$5.25 ➝ $5.00
2/9/2021Maxim GroupReiterated RatingBuy$2.00
9/10/2020TD SecuritiesBoost TargetBuy$4.25 ➝ $5.50
8/18/2020Maxim GroupReiterated RatingBuy$5.00
5/13/2020TD SecuritiesBoost TargetBuy$3.25 ➝ $4.00
4/6/2020Maxim GroupBoost Target$2.00 ➝ $5.00
1/14/2020TD SecuritiesUpgradeBuy$4.25 ➝ $4.50
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 1 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/18/2024
  • 2 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 2 very positive mentions
  • 28 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

AIM ImmunoTech logo
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.
Read More

Today's Range

Now: $0.21
Low: $0.21
High: $0.23

50 Day Range

MA: $0.24
Low: $0.19
High: $0.27

52 Week Range

Now: $0.21
Low: $0.16
High: $0.62

Volume

422,353 shs

Average Volume

296,149 shs

Market Capitalization

$13.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of AIM ImmunoTech?

The following equities research analysts have issued research reports on AIM ImmunoTech in the last year: Ascendiant Capital Markets, and Maxim Group.
View the latest analyst ratings for AIM.

What is the current price target for AIM ImmunoTech?

0 Wall Street analysts have set twelve-month price targets for AIM ImmunoTech in the last year. Their average twelve-month price target is $2.75, suggesting a possible upside of 1,206.4%. Ascendiant Capital Markets has the highest price target set, predicting AIM will reach $4.50 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $1.00 for AIM ImmunoTech in the next year.
View the latest price targets for AIM.

What is the current consensus analyst rating for AIM ImmunoTech?

AIM ImmunoTech currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AIM will outperform the market and that investors should add to their positions of AIM ImmunoTech.
View the latest ratings for AIM.

What other companies compete with AIM ImmunoTech?

Other companies that are similar to AIM ImmunoTech include Janone, Shattuck Labs, Immuneering, AlloVir and Iterum Therapeutics. Learn More about companies similar to AIM ImmunoTech.

How do I contact AIM ImmunoTech's investor relations team?

AIM ImmunoTech's physical mailing address is 2117 SW HIGHWAY 484, OCALA FL, 34473. The company's listed phone number is (352) 448-7797 and its investor relations email address is [email protected]. The official website for AIM ImmunoTech is aimimmuno.com. Learn More about contacing AIM ImmunoTech investor relations.